NICOTROL (nicotine) by Pfizer is pharmacologic action nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. First approved in 1997.
Drug data last refreshed 8h ago
NICOTROL is a nicotine inhalant product approved by the FDA in May 1997 for smoking cessation. It works as a cholinergic nicotinic agonist, binding to nicotinic receptors in the brain and peripheral nervous system to reduce withdrawal symptoms and cravings. The product delivers nicotine through inhalation, providing a pharmacologically active alternative to tobacco while allowing behavioral replacement of the smoking ritual. It competes in the over-the-counter smoking cessation market alongside other nicotine replacement therapies.
Pharmacologic Action Nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Nicotine Influence on the Retina Following the Use of Electronic Cigarette
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Worked on NICOTROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moNICOTROL currently shows zero linked job openings, reflecting its mature, competitive market position with limited growth opportunities. Career roles historically associated with this product would include brand managers, field sales representatives, and patient education specialists, though recruitment is likely minimal given LOE pressures. Success in this space requires expertise in managed care negotiations, generic competition strategies, and consumer health marketing rather than innovative launch or clinical development capabilities.